PRIMARY TESTICULAR LYMPHOMA

May 1, 2025 updated by: Huber Díaz Fuentes, Instituto Mexicano del Seguro Social

PRIMARY TESTICULAR LYMPHOMA WITH EXTRA-NODAL STOMACH AFFECTATION

742 / 5.000 A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.

The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, nontender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.

The left testicle was normal.

He underwent radical orchiectomy, which revealed renal testicular lymphoma.

Study Overview

Status

Completed

Conditions

Detailed Description

A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.

The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, non-tender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.

The left testicle was normal.

He underwent radical orchiectomy, which revealed renal-testicular lymphoma.

On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.

He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a 6 cm bleeding gastric ulcer. A biopsy was taken and a diffuse B-cell lymphoma was detected.

He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.

On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.

He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.

The patient continued to have melena and grade IV anemia. He was referred to pathology, where he was found to have OMS. He showed no improvement despite blood transfusions. He died. Immunohistochemistry for both testicular lesions and on the third postoperative day.

Study Type

Observational

Enrollment (Actual)

1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Mexico
    • Yucatán
      • Mérida, Yucatán, Mexico
        • Instituto Mexicano del Seguro Social

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

57 year old male with testicular lymphoma

Description

Inclusion Criteria:

  • Patient with testicular lymphoma

Exclusion Criteria:

  • Patient without testicular lymphoma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: 3 months
Describe the mortality in primary testicular lymphoma
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Instituto Mexicano del Seguro Social

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Actual)

March 28, 2025

Study Completion (Actual)

March 29, 2025

Study Registration Dates

First Submitted

May 1, 2025

First Submitted That Met QC Criteria

May 1, 2025

First Posted (Actual)

May 9, 2025

Study Record Updates

Last Update Posted (Actual)

May 9, 2025

Last Update Submitted That Met QC Criteria

May 1, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 982121

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

anyone who ask via e-mail

IPD Sharing Time Frame

anytime

IPD Sharing Access Criteria

e-mail

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Testicular Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe